HAE
Haemonetics Corporation
108.40$
+0.7%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -4.2% | +31.1% | +37.9% | -27.7% | -0.7% | -31.2% | +58.3% | +58.5% | -33.4% | 0.0% | +61.4% | |
| – | +4.6% | -0.3% | -0.5% | +22.6% | +0.8% | -23.6% | +16.0% | -4.5% | +4.2% | +18.9% | -3.3% | |
| – | -50.7% | +31.7% | +42.3% | +32.0% | +19.0% | +24.7% | -4.5% | +5.0% | +10.7% | +4.6% | +14.1% | |
| – | +326.4% | -20.5% | -93.9% | +937.4% | +11.2% | -92.6% | +879.0% | -21.8% | – | – | – | |
| – | – | – | – | -182.0% | – | – | – | – | -347.3% | – | – | |
| – | -16.2% | -25.7% | -1.8% | +59.0% | -59.0% | -24.0% | +160.6% | +14.2% | -65.4% | +3.0% | -16.5% | |
| – | -14.0% | -30.0% | -14.0% | +84.2% | -50.8% | +644.1% | -79.7% | +66.5% | +124.2% | -49.8% | +10.9% | |
| – | – | – | – | – | -10.6% | – | – | – | – | – | – | |
| – | +56.2% | – | -403.1% | +60.0% | +9.4% | – | -833.1% | +0.0% | -92.2% | +3,723.3% | -22.2% | |
| – | +105.3% | +366.7% | -34.7% | – | -66.8% | +1,063.1% | -104.7% | – | -86.0% | +1,084.9% | -101.4% | |
| – | +88.9% | -3.5% | +99.7% | -58.0% | +159.2% | – | -104.3% | +537.3% | – | +185.2% | -264.0% | |
| – | – | – | +66.1% | -126.6% | – | – | +22.2% | -62.8% | -523.2% | – | -147.9% | |
| – | +292.5% | +329.6% | +74.1% | -72.3% | +171.5% | -34.4% | +5.6% | +115.0% | -11.8% | -0.8% | +82.8% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.